Responses
Ovarian cancer
2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.